Management of adrenocortical carcinoma in Slovenia: a real-life analysis of histopathologic markers, treatment patterns, prognostic factors, and survival

1. Kerkhofs TM, Verhoeven RH, Van der Zwan JM, Dieleman J, Kerstens MN, Links TP, et al. Adrenocortical carcinoma: a population-based study on incidence and survival in the Netherlands since 1993. Eur J Cancer 2013; 49: 2579-86. doi: 10.1016/j.ejca.2013.02.034 Kerkhofs TM Verhoeven RH Van der Zwan JM Dieleman J Kerstens MN Links TP Adrenocortical carcinoma: a population-based study on incidence and survival in the Netherlands since 1993 . Eur J Cancer 2013 ; 49 : 2579 - 86 . doi: 10.1016/j.ejca.2013.02.034 Open DOISearch in Google Scholar

2. Calabrese A, Basile V, Puglisi S, Perotti P, Pia A, Saba L, et al. Adjuvant mi-totane therapy is beneficial in non-metastatic adrenocortical carcinoma at high risk of recurrence. Eur J Endocrinol 2019; 180: 387-96. doi: 10.1530/eje-18-0923 Calabrese A Basile V Puglisi S Perotti P Pia A Saba L Adjuvant mi-totane therapy is beneficial in non-metastatic adrenocortical carcinoma at high risk of recurrence . Eur J Endocrinol 2019 ; 180 : 387 - 96 . doi: 10.1530/eje-18-0923 Open DOISearch in Google Scholar

3. Fassnacht M, Dekkers OM, Else T, Baudin E, Berruti A, de Krijger RR, et al. European society of endocrinology clinical practice guidelines on the man-agement of adrenocortical carcinoma in adults, in collaboration with the European network for the study of adrenal tumors. Eur J Endocrinol 2018; 179: G1-G46. doi: 10.1530/EJE-18-0608 Fassnacht M Dekkers OM Else T Baudin E Berruti A de Krijger RR European society of endocrinology clinical practice guidelines on the man-agement of adrenocortical carcinoma in adults in collaboration with the European network for the study of adrenal tumors . Eur J Endocrinol 2018 ; 179 : G1 - G46 . doi: 10.1530/EJE-18-0608 Open DOISearch in Google Scholar

4. Gambella A, Volante M, Papotti M. Histopathologic features of adre-nal cortical carcinoma. Adv Anat Pathol 2023; 30: 34-46. doi:10.1097/PAP.0000000000000363 Gambella A Volante M Papotti M. Histopathologic features of adre-nal cortical carcinoma . Adv Anat Pathol 2023 ; 30 : 34 - 46 . doi: 10.1097/PAP.0000000000000363 Open DOISearch in Google Scholar

5. Weiss LM. Comparative histologic study of 43 metastasizing and nonme-tastasizing adrenocortical tumors. Am J Surg Pathol 1984; 8:163-9. doi: 10.1097/00000478-198403000-00001 Weiss LM. Comparative histologic study of 43 metastasizing and nonme-tastasizing adrenocortical tumors . Am J Surg Pathol 1984 ; 8 : 163 - 9 . doi: 10.1097/00000478-198403000-00001 Open DOISearch in Google Scholar

6. Duregon E, Cappellesso R, Maffeis V, Zaggia B, Ventura L, Berruti A, et al. Validation of the prognostic role of the “Helsinki Score„ in 225 cases of adrenocortical carcinoma. Hum Pathol 2017; 62: 1-7. doi: 10.1016/j.hum-path.2016.09.035 Duregon E Cappellesso R Maffeis V Zaggia B Ventura L Berruti A Validation of the prognostic role of the “Helsinki Score„ in 225 cases of adrenocortical carcinoma . Hum Pathol 2017 ; 62 : 1 - 7 . doi: 10.1016/j.hum-path.2016.09.035 Open DOISearch in Google Scholar

7. Phan AT, Grogan RH, Rohren E, Perrier ND. Adrenal cortical carcinoma. In: Amin MB, Edge S, Greene F, Byrd DR, Brookland RK, Washington MK, et al, editors. AJCC Cancer Staging Manual. 8th edition. New York: Springer; 2016. p. 919-26. Phan AT Grogan RH Rohren E Perrier ND. Adrenal cortical carcinoma . In: Amin MB Edge S Greene F Byrd DR Brookland RK Washington MK et al , editors. AJCC Cancer Staging Manual . 8th edition. New York : Springer ; 2016 . p. 919 - 26 . Search in Google Scholar

8. Fassnacht M, Johanssen S, Quinkler M, Bucsky P, Willenberg HS, Beuschlein F, et al. Limited prognostic value of the 2004 International Union Against Cancer staging classification for adrenocortical carcinoma: proposal for a revised TNM classification. Cancer 2009; 155: 243-50. doi: 10.1002/cncr.24030 Fassnacht M Johanssen S Quinkler M Bucsky P Willenberg HS Beuschlein F Limited prognostic value of the 2004 International Union Against Cancer staging classification for adrenocortical carcinoma: proposal for a revised TNM classification . Cancer 2009 ; 155 : 243 - 50 . doi: 10.1002/cncr.24030 Open DOISearch in Google Scholar

9. Terzolo M, Fassnacht M, Perotti P, Libe R, Kastelan D, Lacroix A, et al. Adjuvant mitotane versus surveillance in low-grade, localised adrenocorti-cal carcinoma (ADIUVO): an international, multicentre, open-label, ran-domised, phase 3 trial and observational study. Lancet Diabetes Endocrinol 2023; 11: 720-30. doi: 10.1016/S2213-8587(23)00193-6 Terzolo M Fassnacht M Perotti P Libe R Kastelan D Lacroix A Adjuvant mitotane versus surveillance in low-grade, localised adrenocorti-cal carcinoma (ADIUVO): an international, multicentre, open-label, ran-domised, phase 3 trial and observational study . Lancet Diabetes Endocrinol 2023 ; 11 : 720 - 30 . doi: 10.1016/S2213-8587(23)00193-6 Open DOISearch in Google Scholar

10. Fassnacht M, Terzolo M, Allolio B, Baudin E, Haak H, Berruti A, et al. Combination chemotherapy in advanced adrenocortical carcinoma. N Engl J Med 2012; 366: 2189-97. doi: 10.1056/NEJMoa1200966 Fassnacht M Terzolo M Allolio B Baudin E Haak H Berruti A Combination chemotherapy in advanced adrenocortical carcinoma . N Engl J Med 2012 ; 366 : 2189 - 97 . doi: 10.1056/NEJMoa1200966 Open DOISearch in Google Scholar

11. Naing A, Meric-Bernstam F, Stephen B, Karp DD, Hajjar J, Ahnert JR, et al. Phase 2 study of pembrolizumab in patients with advanced rare cancers. J Immunother Cancer 2020; 8: e000347. doi: 10.1136/jitc-2019-000347 Naing A Meric-Bernstam F Stephen B Karp DD Hajjar J Ahnert JR Phase 2 study of pembrolizumab in patients with advanced rare cancers . J Immunother Cancer 2020 ; 8 : e000347 . doi: 10.1136/jitc-2019-000347 Open DOISearch in Google Scholar

12. Campbell MT, Balderrama-Brondani V, Jimenez C, Tamsen G, Marcal LP, Varghese J, et al. Cabozantinib monotherapy for advanced adrenocortical carcinoma: a single-arm, phase 2 trial. Lancet Oncol 2024; 25: 649-57. doi: 10.1016/S1470-2045(24)00095-0 Campbell MT Balderrama-Brondani V Jimenez C Tamsen G Marcal LP Varghese J Cabozantinib monotherapy for advanced adrenocortical carcinoma: a single-arm, phase 2 trial . Lancet Oncol 2024 ; 25 : 649 - 57 . doi: 10.1016/S1470-2045(24)00095-0 Open DOISearch in Google Scholar

13. Altieri B, Ronchi CL, Kroiss M, Fassnacht M. Next-generation therapies for adrenocortical carcinoma. Best Pract Res Clin Endocrinol Met 2020; 34: 101434. doi: 10.1016/j.beem.2020.101434 Altieri B Ronchi CL Kroiss M Fassnacht M. Next-generation therapies for adrenocortical carcinoma . Best Pract Res Clin Endocrinol Met 2020 ; 34 : 101434 . doi: 10.1016/j.beem.2020.101434 Open DOISearch in Google Scholar

14. Fassnacht M, Assie G, Baudin E, Eisenhofer G, de la Fouchardiere C, Haar HR, et al. Adrenocortical carcinomas and malignant pheochromocytomas: ESMO-EURACAN clinical practice guidelines for diagnosis, treatment and fol-low-up. Ann Oncol 2020; 31: 1476-90. doi: 10.1016/j.annonc.2020.08.2099 Fassnacht M Assie G Baudin E Eisenhofer G de la Fouchardiere C Haar HR Adrenocortical carcinomas and malignant pheochromocytomas: ESMO-EURACAN clinical practice guidelines for diagnosis, treatment and fol-low-up . Ann Oncol 2020 ; 31 : 1476 - 90 . doi: 10.1016/j.annonc.2020.08.2099 Open DOISearch in Google Scholar

15. Beuschlein F, Weigel J, Saeger W, Kroiss M, Wild V, Daffara F, et al. Major prognostic role of Ki67 in localised adrenocortical carcinoma after com-plete resection. J Clin Endocrinol Metab 2015; 100: 841-9. doi: 10.1210/jc.2014-3182 Beuschlein F Weigel J Saeger W Kroiss M Wild V Daffara F Major prognostic role of Ki67 in localised adrenocortical carcinoma after com-plete resection . J Clin Endocrinol Metab 2015 ; 100 : 841 - 9 . doi: 10.1210/jc.2014-3182 Open DOISearch in Google Scholar

16. Libe R, Borget I, Ronchi CL, Zaggia B, Kroiss M, Kerkhofs T, et al. Prognostic factors in stage III-IV adrenocortical carcinomas (ACC): an European network for the study of adrenal tumor (ENSAT) study. Ann Oncol 2015; 26: 2119-25. doi: 10.1093/annonc/mdv329 Libe R Borget I Ronchi CL Zaggia B Kroiss M Kerkhofs T Prognostic factors in stage III-IV adrenocortical carcinomas (ACC): an European network for the study of adrenal tumor (ENSAT) study . Ann Oncol 2015 ; 26 : 2119 - 25 . doi: 10.1093/annonc/mdv329 Open DOISearch in Google Scholar

17. Bisceglia M, Ludovico O, Di Mattia A, Ben-Dor D, Sandbank J, Pasquinelli G, et al. Adrenocortical oncocytic tumors: report of 10 cases and review of the literature. Int J Surg Pathol 2004; 12: 231-43. doi: 10.1177/106689690401200304 Bisceglia M Ludovico O Di Mattia A Ben-Dor D Sandbank J Pasquinelli G Adrenocortical oncocytic tumors: report of 10 cases and review of the literature . Int J Surg Pathol 2004 ; 12 : 231 - 43 . doi: 10.1177/106689690401200304 Open DOISearch in Google Scholar

18. Erickson LA. Challenges in surgical pathology of adrenocortical tumours. Histopathology 2018; 72: 82-96. doi: 10.1111/his.13255 Erickson LA. Challenges in surgical pathology of adrenocortical tumours . Histopathology 2018 ; 72 : 82 - 96 . doi: 10.1111/his.13255 Open DOISearch in Google Scholar

19. Laubert T, Habermann JK, Hemmelmann C, Kleemann M, Oevermann E, Bouchard R, et al. Metachronous metastasis-and survival-analysis show prognostic importance of lymphadenectomy for colon carcinomas. BMC Gastroenterol 2012; 12: 24. doi: 10.1186/1471-230X-12-24 Laubert T Habermann JK Hemmelmann C Kleemann M Oevermann E Bouchard R Metachronous metastasis-and survival-analysis show prognostic importance of lymphadenectomy for colon carcinomas . BMC Gastroenterol 2012 ; 12 : 24 . doi: 10.1186/1471-230X-12-24 Open DOISearch in Google Scholar

20. Didolkar MS, Bescher RA, Elias EG, Moore RH. Natural history of adre-nal cortical carcinoma: a clinicopathologic study of 42 patients. Cancer 1981; 47: 2153-61. doi: 10.1002/1097-0142(19810501)47:9<3C2153:aid-cncr2820470908>3E3.0.co;2-6 Didolkar MS Bescher RA Elias EG Moore RH. Natural history of adre-nal cortical carcinoma: a clinicopathologic study of 42 patients . Cancer 1981 ; 47 : 2153 - 61 . doi: 10.1002/1097-0142(19810501)47:9<3C2153:aid-cncr2820470908>3E3.0.co;2-6 Open DOISearch in Google Scholar

21. Wooten MD, King DK. Adrenal cortical carcinoma. Epidemiology and treatment with mitotane and a review of the literature. Cancer 1993; 72: 3145-55. doi: 10.1002/1097-0142(19931201)72:11<3145::AID-CNCR2820721105>3.0.CO;2-N Wooten MD King DK. Adrenal cortical carcinoma . Epidemiology and treatment with mitotane and a review of the literature. Cancer 1993 ; 72 : 3145 - 55 . doi: 10.1002/1097-0142(19931201)72:11<3.0.CO;2-N Open DOISearch in Google Scholar

22. Souteiro P, Donato S, Costa C, Pereira CA, Simoes-Pereira J, Oliveira J, et al. Diagnosis, treatment and survival analysis of adrenocortial carcinomas: a multicentric study. Hormones 2020; 19: 197-203. doi: 10.1007/s42000-019-00161-1 Souteiro P Donato S Costa C Pereira CA Simoes-Pereira J Oliveira J Diagnosis, treatment and survival analysis of adrenocortial carcinomas: a multicentric study . Hormones 2020 ; 19 : 197 - 203 . doi: 10.1007/s42000-019-00161-1 Open DOISearch in Google Scholar

23. Kostiainen I, Hakaste L, Kejo P, Parviainen H, Laine T, Löyttyniemi E, et al. Adrenocortical carcinoma: presentation and outcome of a contemporary patient series. Endocrine 2019; 65: 166-74. doi:10.1007/s12020-019-01918-9 Kostiainen I Hakaste L Kejo P Parviainen H Laine T Löyttyniemi E Adrenocortical carcinoma: presentation and outcome of a contemporary patient series . Endocrine 2019 ; 65 : 166 - 74 . doi: 10.1007/s12020-019-01918-9 Open DOISearch in Google Scholar

24. Margonis GA, Kim Y, Prescott JD, Tran TB, Postlewait LM, Maithel SK, et al. Adrenocortical carcinoma: Impact of surgical margin status on long-term outcomes. Ann Surg Oncol 2016; 23: 134-41. doi: 10.1245/s10434-015-4803-x Margonis GA Kim Y Prescott JD Tran TB Postlewait LM Maithel SK Adrenocortical carcinoma: Impact of surgical margin status on long-term outcomes . Ann Surg Oncol 2016 ; 23 : 134 - 41 . doi: 10.1245/s10434-015-4803-x Open DOISearch in Google Scholar

25. Fassnacht M, Allolio B. Clinical management of adrenocortical carcinoma. Best Pract Res Clin Endocrinol Metabol 2009; 23: 273-89. doi: 10.1016/j.beem.2008.10.008 Fassnacht M Allolio B. Clinical management of adrenocortical carcinoma . Best Pract Res Clin Endocrinol Metabol 2009 ; 23 : 273 - 89 . doi: 10.1016/j.beem.2008.10.008 Open DOISearch in Google Scholar

26. Puglisi S, Calabrese A, Ferrau F, Violi MA, Lagana M, Grisanti S, et al. New findings on presentation and outcome of patients with adrenocortical can-cer: results from a national cohort study. J Clin Endocrinol Metab 2023; 108: 2517-25. doi: 10.1210/clinem/dgad199 Puglisi S Calabrese A Ferrau F Violi MA Lagana M Grisanti S New findings on presentation and outcome of patients with adrenocortical can-cer: results from a national cohort study . J Clin Endocrinol Metab 2023 ; 108 : 2517 - 25 . doi: 10.1210/clinem/dgad199 Open DOISearch in Google Scholar

27. Chortis V, Taylor AE, Schneider P, Tomlinson JW, Hughes BA, O’Neil DM, et al. Mitotane therapy in adrenocortical cancer induces CYP3A4 and inhibits 5α -reductase, explaining the need for personalized glucocorticoid and androgen replacement. J Clin Endocrinol Metab 2013; 98: 161-71. doi: 10.1210/jc.2012-2851 Chortis V Taylor AE Schneider P Tomlinson JW Hughes BA O’Neil DM Mitotane therapy in adrenocortical cancer induces CYP3A4 and inhibits 5± -reductase, explaining the need for personalized glucocorticoid and androgen replacement . J Clin Endocrinol Metab 2013 ; 98 : 161 - 71 . doi: 10.1210/jc.2012-2851 Open DOISearch in Google Scholar

28. Henning JE, Deutschbein T, Altieri B, Steinhauer S, Kircher S, Sbiera S, et al Gemcitabine-based chemotherapy in adrenocortical carcinoma: a multicen-tre study of efficacy and predictive factors. J Clni Endocrinol Metab 2017; 102: 4323-32. doi: 10.1210/jc.2017-01624 Henning JE Deutschbein T Altieri B Steinhauer S Kircher S Sbiera S Gemcitabine-based chemotherapy in adrenocortical carcinoma: a multicen-tre study of efficacy and predictive factors . J Clni Endocrinol Metab 2017 ; 102 : 4323 - 32 . doi: 10.1210/jc.2017-01624 Open DOISearch in Google Scholar

29. Kroiss M, Deutschbein T, Schlötelburg W, Ronchi CL, Hescot S, Körbl D, et al. Treatment of refractory adrenocortical carcinoma with thalidomide: analysis of 27 patients from the European Network for the Study of Adrenal Tumours registry. Exp Clin Endocrinol Diabetes 2019; 127: 578-84. doi: 10.1055/a-0747-5571 Kroiss M Deutschbein T Schlötelburg W Ronchi CL Hescot S Körbl D Treatment of refractory adrenocortical carcinoma with thalidomide: analysis of 27 patients from the European Network for the Study of Adrenal Tumours registry . Exp Clin Endocrinol Diabetes 2019 ; 127 : 578 - 84 . doi: 10.1055/a-0747-5571 Open DOISearch in Google Scholar

30. Owen DH, Patel S, Wei L, Phay JE, Shirley LA, Kirschner LS, et al. Metastatic adrenocortical carcinoma: a single institutional experience. Horm Cancer 2019; 10: 161-7. doi: 10.1007/s12672-019-00367-0 Owen DH Patel S Wei L Phay JE Shirley LA Kirschner LS Metastatic adrenocortical carcinoma: a single institutional experience . Horm Cancer 2019 ; 10 : 161 - 7 . doi: 10.1007/s12672-019-00367-0 Open DOISearch in Google Scholar

31. Hescot S, Debien V, Hadoux J, Drui D, Haissaguerre M, de la Fouchardiere C, et al. Outcome of adrenocortical carcinoma patients included in early phase clinical trials: Results from the French network ENDOCAN-COMETE. Eur J Cancer 2023; 189: 112917. doi: 10.1016/j.ejca.2023.05.006 Hescot S Debien V Hadoux J Drui D Haissaguerre M de la Fouchardiere C Outcome of adrenocortical carcinoma patients included in early phase clinical trials: Results from the French network ENDOCAN-COMETE . Eur J Cancer 2023 ; 189 : 112917 . doi: 10.1016/j.ejca.2023.05.006 Open DOISearch in Google Scholar

32. Kimpel O, Schindler P, Schmidt-Pennington L, Altieri B, Megerle F, Haak H. et al. Efficacy and safety of radiation therapy in advanced adrenocortical car-cinoma. Br J Cancer 2023; 128: 586-93. doi: 10.1038/s41416-022-02082-0 Kimpel O Schindler P Schmidt-Pennington L Altieri B Megerle F Haak H. Efficacy and safety of radiation therapy in advanced adrenocortical car-cinoma . Br J Cancer 2023 ; 128 : 586 - 93 . doi: 10.1038/s41416-022-02082-0 Open DOISearch in Google Scholar

33. Calabrese A, Puglisi S, Borin C, Basile V, Perotti P, Pia A, et al. The manage-ment of postoperative disease recurrence in patients with adrenocortical carcinoma: a retrospective study in 106 patients. Eur J Endocrinol 2023; 188: 118-24. doi: 10.1093/ejendo/lvad002 Calabrese A Puglisi S Borin C Basile V Perotti P Pia A The manage-ment of postoperative disease recurrence in patients with adrenocortical carcinoma: a retrospective study in 106 patients . Eur J Endocrinol 2023 ; 188 : 118 - 24 . doi: 10.1093/ejendo/lvad002 Open DOISearch in Google Scholar

34. Pennanen M, Heiskanen I, Sane T, Remes S, Mustonen H, Haglund C, et al. Helsinki score-a novel model for prediction of metastases in adreno-cortical carcinomas. Hum Pathol 2015; 46: 404-10. doi: 10.1016/j.hump-ath.2014.11.015 Pennanen M Heiskanen I Sane T Remes S Mustonen H Haglund C Helsinki score-a novel model for prediction of metastases in adreno-cortical carcinomas . Hum Pathol 2015 ; 46 : 404 - 10 . doi: 10.1016/j.hump-ath.2014.11.015 Open DOISearch in Google Scholar

35. Pato E, Srougi V, Zerbini C, Ledesma FL, Tanno F, Almeida MQ, et al. Clinical and pathological predictors of death for adrenocortical carcinoma. J Endocr Soc 2024; 8: 1-6. doi: 10.1210/jendso/bvad170 Pato E Srougi V Zerbini C Ledesma FL Tanno F Almeida MQ Clinical and pathological predictors of death for adrenocortical carcinoma . J Endocr Soc 2024 ; 8 : 1 - 6 . doi: 10.1210/jendso/bvad170 Open DOISearch in Google Scholar

36. Mete O, Gucer H, Kefeli M, Asa SL. Diagnostic and prognostic biomarkers of adrenal cortical carcinoma. Am J Surg Pathol 2018; 42: 201-13. doi: 10.1097/PAS.0000000000000943 Mete O Gucer H Kefeli M Asa SL. Diagnostic and prognostic biomarkers of adrenal cortical carcinoma . Am J Surg Pathol 2018 ; 42 : 201 - 13 . doi: 10.1097/PAS.0000000000000943 Open DOISearch in Google Scholar

37. Giordano TJ. The argument for mitotic rate-based grading for the prognos-tication of adrenocortical carcinoma. Am J Surg Pathol 2011; 35: 471-3. doi: 10.1097/PAS.0b013e31820bcf21 Giordano TJ. The argument for mitotic rate-based grading for the prognos-tication of adrenocortical carcinoma . Am J Surg Pathol 2011 ; 35 : 471 - 3 . doi: 10.1097/PAS.0b013e31820bcf21 Open DOISearch in Google Scholar

38. Martins-Filho SN, Almeida MQ, Soares I, Wakamatsu A, Alves VAF, Fragoso MCBV, et al. Clinical impact of pathological features including the Ki-67 labeling index on diagnosis and prognosis of adult and pediatric adreno-cortical tumors. Endocr Pathol 2021; 32: 288-300. doi: 10.1007/s12022-020-09654-x Martins-Filho SN Almeida MQ Soares I Wakamatsu A Alves VAF Fragoso MCBV Clinical impact of pathological features including the Ki-67 labeling index on diagnosis and prognosis of adult and pediatric adreno-cortical tumors . Endocr Pathol 2021 ; 32 : 288 - 300 . doi: 10.1007/s12022-020-09654-x Open DOISearch in Google Scholar

39. Morimoto R, Satoh F, Murakami O, Suzuki T, Abe T, Tanemoto M, et al. Immunohistochemistry of a proliferation marker Ki67/MIB1 in adrenocorti-cal carcinomas: Ki67/MIB1 labeling index is a predictor for recurrence of adrenocortical carcinoma. Endocr J 2008; 55: 49-55. doi: 10.1507/endocrj.k07-079 Morimoto R Satoh F Murakami O Suzuki T Abe T Tanemoto M Immunohistochemistry of a proliferation marker Ki67/MIB1 in adrenocorti-cal carcinomas: Ki67/MIB1 labeling index is a predictor for recurrence of adrenocortical carcinoma . Endocr J 2008 ; 55 : 49 - 55 . doi: 10.1507/endocrj.k07-079 Open DOISearch in Google Scholar

40. Luconi M, Cantini G, van Leeuwaarde RS, Roebaar R, Fei L, Propato AP, et al. Prognostic value of microscopic tumor necrosis in adrenal cortical carci-noma. Endocr Pathol 2023; 34: 224-33. doi: 10.1007/s12022-023-09760-6 Luconi M Cantini G van Leeuwaarde RS Roebaar R Fei L Propato AP Prognostic value of microscopic tumor necrosis in adrenal cortical carci-noma . Endocr Pathol 2023 ; 34 : 224 - 33 . doi: 10.1007/s12022-023-09760-6 Open DOISearch in Google Scholar

41. Angelousi A, Kyriakopoulos G, Athanasouli F, Dimitriadi A, Kassi E, Aggeli C, et al. The role of immunohistochemical markers for the diagnosis and prognosis of adrenocortical neoplasms. J Pers Med 2021; 11: 208. doi: 10.3390/jpm11030208 Angelousi A Kyriakopoulos G Athanasouli F Dimitriadi A Kassi E Aggeli C The role of immunohistochemical markers for the diagnosis and prognosis of adrenocortical neoplasms . J Pers Med 2021 ; 11 : 208 . doi: 10.3390/jpm11030208 Open DOISearch in Google Scholar

42. Kareem T, Kimler BF, Davis MK, Fan F, Tawfik O. Ki-67 expression in axillary lymph node metastases in breast cancer is prognostically significant. Hum Pathol 2013; 44: 39-46. doi: 10.1016/j.humpath.2012.05.00 Kareem T Kimler BF Davis MK Fan F Tawfik O. Ki-67 expression in axillary lymph node metastases in breast cancer is prognostically significant . Hum Pathol 2013 ; 44 : 39 - 46 . doi: 10.1016/j.humpath.2012.05.00 Open DOISearch in Google Scholar

43. Falato C, Lorent J, Tani E, Karlsson E, Wright PK, Bergh J, et al. Ki67 meas-ured in metastatic tissue and prognosis in patients with advanced breast cancer. Breast Cancer Res Treat 2014; 147: 407-14. doi: 10.1007/s10549-014-3096-2 Falato C Lorent J Tani E Karlsson E Wright PK Bergh J Ki67 meas-ured in metastatic tissue and prognosis in patients with advanced breast cancer . Breast Cancer Res Treat 2014 ; 147 : 407 - 14 . doi: 10.1007/s10549-014-3096-2 Open DOISearch in Google Scholar

44. Tizianel I, Caccese M, Torresan F, Lombardi G, Evangelista L, Crimì F, et al. The overall survival and progression-free survival in patients with advanced adrenocortical cancer is increased after the multidisciplinary team evalua-tion. Cancers 2022; 14: 3904. doi: 10.3390/cancers14163904 Tizianel I Caccese M Torresan F Lombardi G Evangelista L Crimì F The overall survival and progression-free survival in patients with advanced adrenocortical cancer is increased after the multidisciplinary team evalua-tion . Cancers 2022 ; 14 : 3904 . doi: 10.3390/cancers14163904 Open DOISearch in Google Scholar